Latest news with #FisherPaykel
Yahoo
11-08-2025
- Business
- Yahoo
[Latest] Global High Flow Nasal Cannula Market Size/Share Worth USD 5.9 Billion by 2034 at a 5.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global High Flow Nasal Cannula Market size & share revenue was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.7 Billion in 2025 and is expected to reach around USD 5.9 Billion by 2034, at a CAGR of 5.4% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Vapotherm Inc., Armstrong Medical Ltd, Salter Labs Inc, ResMed Inc., Teleflex Inc, BD, Smiths Medical, Flexicare Medical Ltd, Teijin Pharma Limited, TNI Medical AG, Fisher & Paykel Healthcare Limited, Hamilton Medical AG, Drägerwerk AG & Co. KGaA, Heka Medicals India Pvt Ltd., GaleMed Corporation and others. Austin, TX, USA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'High Flow Nasal Cannula Market Size, Trends and Insights By Product Type (Single Heated Tube, Nasal Cannula, Active Humidifier, Air Blender), By Application (Acute Respiratory Failure, Chronic Obstructive Pulmonary Disease, Acute Heart Failure, Others), By End User (Hospitals and Clinics, Ambulatory Care Centers, Long-term Care Centers, Others), By Sales Channel (Direct Channel, Indirect Channel), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034' in its research database.'According to the latest research study, the demand of global High Flow Nasal Cannula Market size & share was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.7 Billion in 2025 and is expected to reach a value of around USD 5.9 Billion by 2034, at a compound annual growth rate (CAGR) of about 5.4% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global High Flow Nasal Cannula Market @ High Flow Nasal Cannula Market Overview According to industry experts at CMI, High Flow nasal cannula (HFNC) is a non-invasive respiratory support system where heated, humidified oxygen is delivered at high flow rates using a nasal cannula. In pediatric care environments and for individuals with either abrupt respiratory failure or chronic obstructive pulmonary disease (COPD), HFNC is especially crucial. Its primary application is in a range of healthcare environments, including home healthcare environments, emergency departments, and intensive care units (ICUs). As stresses on the global healthcare systems, including a rise in patient count and a spectrum of respiratory discomfort cases, continue to mount, the demand for HFNC devices has been rising. The key drivers of this market are technological improvements, increasing awareness and acceptance rates among medical specialists, and the higher sensitivity of the aging population to respiratory diseases. Emerging markets show the most recent probable opportunities in this sector since awareness campaigns can boost usage and healthcare infrastructure is developing there. Request a Customized Copy of the High Flow Nasal Cannula Market Report @ High Flow Nasal Cannula Market Growth Factors and Dynamics Growing geriatric population The growing geriatric population is a major driving factor for the high-flow nasal cannula (HFNC) market. Since chronic obstructive pulmonary disease (COPD) and other respiratory diseases are more common in this age group, which makes HNFC an attractive option. Furthermore, the older population is increasingly inclining towards non-invasive respiratory support techniques. For instance, 80% of older people will reside in developing areas by 2050, as per the World Health Organization. Advancement in technology The High Flow Nasal Cannulas (HFNC) market is expanding rapidly because of the technological development. Presently, HFNC devices are safer, more effective, and simpler to use, which fuels their use in clinical settings. To maintain proper moisture and temperature levels, modern HFNC systems employ sophisticated humidification procedures that enhance patient comfort and reduce airway discomfort. Also, touch-screen controllers and user-friendly interfaces have also helped medical professionals operating equipment by enabling precise monitoring and adjustments. Thereby driving the market growth. (A free sample of the High Flow Nasal Cannula report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the High Flow Nasal Cannula report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the High Flow Nasal Cannula Market Report @ Limited awareness and training Healthcare practitioners' ignorance and lack of training significantly hampered the high-flow nasal cannula (HFNC) market, especially in developing regions. Many healthcare professionals' insufficient awareness of the characteristics and benefits of HFNC devices causes underutilization and slower market penetration. Moreover, effective usage of HFNC devices depends on certain training. Request a Customized Copy of the High Flow Nasal Cannula Market Report @ Key questions answered in this report: What is the size of the High Flow Nasal Cannula market and what is its expected growth rate? What are the primary driving factors that push the High Flow Nasal Cannula market forward? What are the High Flow Nasal Cannula Industry's top companies? What are the different categories that the High Flow Nasal Cannula Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the High Flow Nasal Cannula market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium High Flow Nasal Cannula Research Report | Fast Delivery Available - [220+ Pages] @ Report Scope Feature of the Report Details Market Size in 2025 USD 3.7 Billion Projected Market Size in 2034 USD 5.9 Billion Market Size in 2024 USD 3.5 Billion CAGR Growth Rate 5.4% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Product Type, Application, End User, Sales Channel and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. Request a Customized Copy of the High Flow Nasal Cannula Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'High Flow Nasal Cannula Market Size, Trends and Insights By Product Type (Single Heated Tube, Nasal Cannula, Active Humidifier, Air Blender), By Application (Acute Respiratory Failure, Chronic Obstructive Pulmonary Disease, Acute Heart Failure, Others), By End User (Hospitals and Clinics, Ambulatory Care Centers, Long-term Care Centers, Others), By Sales Channel (Direct Channel, Indirect Channel), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034' Report at High Flow Nasal Cannula Market Regional Analysis North America is projected to dominate the high flow nasal cannula market. This is because of the region's growing disease prevalence, developed infrastructure, and the strong presence of important players. In addition, a few additional factors driving market expansion in North America include expanding air pollution, an aging population, and an increasing need for fast-acting and highly effective medications. However, the Asia Pacific is projected to capture the significant market share in 2024. This is due to the rising prevalence of smoking. Moreover, the shift towards home healthcare drives the industry expansion. Click Here to Access a Free Sample Report of the Global High Flow Nasal Cannula Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: US Veterinary Diagnostics Market: US Veterinary Diagnostics Market Size, Trends and Insights By Product (Consumables, Reagents, Kits, Equipment & Instruments), By Testing Category (Clinical Chemistry, Microbiology, Parasitology, Histopathology, Cytopathology, Hematology, Immunology & Serology, Imaging, Molecular Diagnostics), By Animal Type (Production Animals, Cattle, Poultry, Swine, Companion Animals, Dogs, Cats, Horses), By End-use (Reference Laboratories, Veterinarians, Animal Owners/Producers), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Europe Testosterone Replacement Therapy Market: Europe Testosterone Replacement Therapy Market Size, Trends and Insights By Product Type (Injectables, Topical, Others), By Active Ingredient (Testosterone Undecanoate, Testosterone Cypionate, Testosterone Enanthate, Testosterone, Others), By End User (Hospitals, Clinics), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Plastic Surgery Instruments Market: Plastic Surgery Instruments Market Size, Trends and Insights By Type (Handheld Instruments, Electrosurgical Instruments, Others), By Procedure (Cosmetic Surgery, Reconstructive Surgery), By End User (Hospitals, Dermatology Clinics, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Canine Orthopedics Market: Canine Orthopedics Market Size, Trends and Insights By Product Type (Implants (plates, screws, pins, joint replacements), Instruments (drills, saws, fixation tools), Orthopedic Supports & Braces), By Procedure Type (Cruciate Ligament Repair, Hip and Elbow Dysplasia Treatment, Fracture Repair and Trauma Surgery), By End User (Veterinary Hospitals & Clinics, Veterinary Research Institutes, Pet Rehabilitation & Therapy Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 Veterinary Regenerative Medicine Market: Veterinary Regenerative Medicine Market Size, Trends and Insights By Product Type (Stem Cells, Gene Therapy, Platelet-Rich Plasma, Tissue Engineering Products, Others), By Application (Orthopedic & Musculoskeletal Disorders, Wound Healing, Dermatology, Others), By Animal Type (Companion Animals, Livestock Animals, Others), By End User (Veterinary Clinics, Veterinary Hospitals, Academic & Research Institutes, Biotech/Pharmaceutical Companies, Veterinary Rehabilitation Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Nuclear Cardiology Market: Nuclear Cardiology Market Size, Trends and Insights By Product Type (Radiopharmaceuticals, Technetium-99m, Thallium-201, Rubidium-82, Others, Imaging Equipment, SPECT Systems, PET Systems, Hybrid Imaging Systems (SPECT/CT, PET/CT)), By Diagnostic Procedure (Myocardial Perfusion Imaging (MPI), Gated SPECT, Cardiac PET Imaging, Multi-Gated Acquisition (MUGA) Scan), By Indication (Coronary Artery Disease (CAD), Heart Failure, Cardiomyopathy, Valvular Heart Disease, Others (e.g., Arrhythmias)), By End User (Hospitals, Cardiology Centers, Diagnostic Imaging Centers, Academic & Research Institutes), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Hologic Mammography Market: Hologic Mammography Market Size, Trends and Insights By Technology (Digital Mammography (2D), Digital Breast Tomosynthesis (3D), Contrast-Enhanced Mammography, AI Enhanced Systems), By Product Type (Mammography Systems, Biopsy Systems, Workstations & Software, Accessories & Detectors), By End User (Hospitals, Diagnostic Imaging Centers, Breast Care Clinics & Specialized Oncology Centers, Academic & Research Institutes), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 US Personalized Medicine Market: US Personalized Medicine Market Size, Trends and Insights By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Nutrition and Wellness), By Application (Oncology, CNS, Immunology, Respiratory, Liver, Rheumatology), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Genetics, Liquid Biopsy, Others (Predictive Modeling, Imaging)), By End-user (Hospitals, Diagnostic Centers, Research & Academic Institutes), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034List of the prominent players in the High Flow Nasal Cannula Market: Vapotherm Inc. Armstrong Medical Ltd Salter Labs Inc ResMed Inc. Teleflex Inc BD Smiths Medical Flexicare Medical Ltd Teijin Pharma Limited TNI Medical AG Fisher & Paykel Healthcare Limited Hamilton Medical AG Drägerwerk AG & Co. KGaA Heka Medicals India Pvt Ltd. GaleMed Corporation Others Click Here to Get a Free Sample Report of the Global High Flow Nasal Cannula Market @ The High Flow Nasal Cannula Market is segmented as follows: By Product Type Single Heated Tube Nasal Cannula Active Humidifier Air Blender By Application Acute Respiratory Failure Chronic Obstructive Pulmonary Disease Acute Heart Failure Others By End User Hospitals and Clinics Ambulatory Care Centers Long-term Care Centers Others By Sales Channel Direct Channel Indirect Channel Click Here to Get a Free Sample Report of the Global High Flow Nasal Cannula Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This High Flow Nasal Cannula Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This High Flow Nasal Cannula Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the High Flow Nasal Cannula Market? What Was the Capacity, Production Value, Cost and PROFIT of the High Flow Nasal Cannula Market? What Is the Current Market Status of the High Flow Nasal Cannula Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of High Flow Nasal Cannula Market by Considering Applications and Types? What Are Projections of the Global High Flow Nasal Cannula Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is High Flow Nasal Cannula Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On High Flow Nasal Cannula Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of High Flow Nasal Cannula Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for High Flow Nasal Cannula Industry? Click Here to Access a Free Sample Report of the Global High Flow Nasal Cannula Market @ Reasons to Purchase High Flow Nasal Cannula Market Report High Flow Nasal Cannula Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. High Flow Nasal Cannula Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. High Flow Nasal Cannula Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. High Flow Nasal Cannula Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global High Flow Nasal Cannula market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium High Flow Nasal Cannula Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide High Flow Nasal Cannula market analysis. The competitive environment of current and potential participants in the High Flow Nasal Cannula market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide High Flow Nasal Cannula market should find this report useful. The research will be useful to all market participants in the High Flow Nasal Cannula industry. Managers in the High Flow Nasal Cannula sector are interested in publishing up-to-date and projected data about the worldwide High Flow Nasal Cannula market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in High Flow Nasal Cannula products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the High Flow Nasal Cannula Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium High Flow Nasal Cannula Research Report | Fast Delivery Available - [220+ Pages] @
Yahoo
28-05-2025
- Business
- Yahoo
Fisher & Paykel Healthcare Corp Ltd (FSPKF) Full Year 2025 Earnings Call Highlights: Robust ...
Operating Revenue: $2.02 billion, up 16% on FY24, 14% in constant currency. Net Profit After Tax: $377.2 million, up 43% on FY24, 30% in constant currency. Hospital Operating Revenue: $1.28 billion, up 18% on FY24, 16% in constant currency. Homecare Operating Revenue: $739.9 million, up 13% on FY24, 11% in constant currency. Gross Margin: 62.9%, increase of 181 basis points, 129 basis points in constant currency. Operating Margin: 25.2%, increase of 379 basis points, 260 basis points in constant currency. R&D Expenses: $227 million, 14% growth, 11% of revenue. SG&A Expenses: $534 million, increase of 8% in both reported and constant currency. Operating Cash Flow: $549 million, up 28% from last year. Capital Expenditure: $103 million, down from $339 million last year. Net Cash: $200.5 million as of March 31. Final Dividend: $0.24 per share, 2% increase from last year. Full-Year Dividend: $0.425 per share, up 2% from last year, 66% payout of full-year profit. Foreign Currency Impact: Positive impact of $39 million on NPAT compared to last year. Warning! GuruFocus has detected 11 Warning Signs with FSPKF. Release Date: May 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Fisher & Paykel Healthcare Corp Ltd (FSPKF) reported a 16% increase in operating revenue, reaching $2.02 billion for the full year. Net profit after tax rose by 43% to $377.2 million, showcasing strong financial performance. The company successfully launched new products, including the Nova Nasal mask and Airvo 3, contributing to growth in both hospital and homecare segments. Gross margin improved by 181 basis points, driven by manufacturing and overhead efficiencies. Operating cash flow increased by 28% to $549 million, reflecting robust profit growth and efficient cash management. Global tariffs are expected to impact gross margin by approximately 75 basis points annually, posing a challenge to margin improvement. The company faces variability in hospital revenue due to seasonal respiratory hospitalizations, which could affect financial outcomes. Operating expenses grew by 10%, which, although expected, indicates rising costs that need to be managed. The OSA mask revenue growth slowed in the second half due to competitive pressures, highlighting market challenges. The company anticipates a longer timeline to achieve its target gross margin of 65% due to ongoing tariff impacts. Q: Can you provide insights into the revenue guidance for FY26, particularly regarding the hospital segment and new product contributions? A: Lewis Gradon, CEO, explained that all new products contribute to the revenue, typically impacting by 1% to 2% annually. Products like the Optiflow Switch and Airvo 3 are part of a long-term rollout strategy, contributing to the overall growth. Q: What factors contributed most to the gross margin expansion, and what should we expect for FY26? A: Lyndal York, CFO, noted that improvements in overhead efficiency and freight contributed significantly to the margin expansion. For FY26, a 100 basis points improvement in constant currency is expected, with freight remaining flat and overhead efficiency reducing in quantum. Q: How is the rollout and penetration of Airvo 3 progressing, particularly in the U.S.? A: Lewis Gradon, CEO, stated that Airvo 3 facilitates clinical practice changes, making it easier for hospitals to adopt. In the U.S., Airvo 3 accounts for about half of the current volume, and continued growth is expected. Q: Can you discuss the impact of tariffs on gross margins and any pricing strategies to mitigate this? A: Lewis Gradon, CEO, mentioned that tariffs could impact gross margins by 75 basis points annually. The company plans to offset this through continuous improvement efforts and routine pricing negotiations, aiming for a net 50 basis points improvement in constant currency. Q: What are the expectations for anesthesia consumables growth in FY26? A: Lewis Gradon, CEO, expects anesthesia consumables to grow by 30% to 40% in FY26, supported by ongoing investments in the sales force to match business growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
News.com.au
28-05-2025
- Business
- News.com.au
Health Check: Fisher & Paykel Healthcare defies the hospital cost crunch with record revenue
Fisher & Paykel Healthcare posts record full-year revenue and shrugs off the US tariff threat Truscreen signs Indian distributor Renerve is off to the Middle East New Zealand-based medical devices supplier Fisher & Paykel Healthcare (ASX:FPH) has shrugged off hospital budgetary pressures to post record revenue for the year to March of NZ$2.2 billion ($1.98 billion), 16% higher. Net profit surged 43%, to NZ$377 million. Assuming currencies remain constant, management has guided to current-year revenue of NZ$2.15 billion to NZ$2.25 billion. Net profit is expected to come in at NZ$390-$440 million. Crucially, this includes a 50-basis point impact of US tariffs on hospital products sourced from New Zealand. 'Our actions in response to any trade policy developments will be driven by our longstanding approach, which is to mitigate cost increases," CEO Lewis Gradon says. This will be "by identifying and implementing continuous improvements and efficiency gains across all of our business processes." The $19 billion market cap FPH's products cover respiratory and healthcare. These include humidifiers, nasal cannulas and devices for high-flow therapy, anaesthesia and laparoscopic and open surgery. FPH's obstructive sleep apnoea (OSA) masks and pumps compete directly with sector Big Daddy ResMed (ASX:RMD), especially in the US market. Global reach FPH demerged from mothership Fisher & Paykel Industries in 2001 and listed on the Australian and Kiwi bourses. While FPH sells in 120 countries, 48% of its revenue derives from the US. Revenue from FPH's hospital products – those used in respiratory, acute and surgical care – gained 18% to NZ$1.28 billion. Hospital sales were driven by the company's launch of a new nasal high flow device, Airvo 3. Homecare, which includes the OSA pumps and masks, rose 13% to NZ$740 million. However, growth in this sector slowed in the second half, partly because of rivals introducing new masks in the US. The business hopes to offset the impact with the recently launch of two new OSA masks, Nova Micro and Nova Nasal. The company's gross margin improved 181 basis points to 62.9%, but still is below the long-term target of 65% and 66.9% just before the pandemic. 'Everything we did around the business made a positive impact,' said CFO Lyndal York, noting reduced freight costs. 'We are back to business as usual.' Gradon said the hospital cost pressures were not new. 'I can't remember a time when these cost pressures didn't exist, or we felt like it had any material impact on us.' On tariffs, management assumes the US impost of 10% on NZ goods will remain, although the company also manufactures in Mexico and China. At least one product range – the OSA masks – look to be protected by the Nairobi Protocol. This global agreement stipulates duty-free treatment of devices for the 'disabled'. The board declared a final dividend of NZ24 cent per share, taking the full-year payout to NZ42.5 cents (up 2%). FPH shares were about 3% off the pace this morning – presumably because of some second half weakness - but have gained 30% over the last 12 months. Truscreen strengthens its Indian foray We're still on Kiwi companies. The maker of a cervical cancer test that can be used without access to labs, Truscreen Group (ASX:TRU) has been anointed the Indian distributor of its Chinese partner's in-vitro diagnostic, for human papilloma virus (HPV). The compact is with Hangzhou Dalton Bioscience Limited. This company makes DNA-based HPV tests as well as lab equipment for cervical cancer screening. Truscreen notes that co-testing its eponymous AI-powered test with the HPV assay has increased the effectiveness of its own test. A Chinese study showed a co-testing sensitivity rate – the ability to detect the disease – of 98.4% compared with Truscreen's 'already impressive' stand-alone 87.5%. Truscreen recently re-entered India with its own test, via local distributor Renovate Biologicals. Truscreen CEO Marty Dillon says the tie-up 'strengthens our product offering in the world's second most populous country and is a blueprint for similar agreements ... for other markets". On that note, Truscreen currently sells its test in China and last month began a large-scale screening program in Vietnam's Ho Chi Minh City. Including Indonesia, the company has a presence in three of the four most popular nations (the US – which it's not targeting – is the glaring exception). On Monday, Truscreen reported revenue of NZ$1.71 million for the year to March. This was down 18%, with a net loss of NZ$2.24 million compared with a previous NZ$2.05 million deficit. Management attributed the revenue dip to delays in its Vietnam and Zimbabwe rollouts, as well as tardy product registration in Indonesia and Uzbekistan. The company flags current year revenue of NZ$2.8 million. Renerve wins Bahrain approval Peripheral nerve repair outfit ReNerve (ASX:RNV) has won marketing consent for its flagship product in Bahrain, its first approval in the promising Middle Eastern region. The approval was by way of Renerve's partnership with its Middle Eastern partner, Union Mediscience BSC. The product is the Nervalign Nerve Cuff, a protective wrap naturally absorbed within six months of surgery. The device already is approved in the US, where it is making a 'dramatic difference' to surgical results. The Middle East/North Africa market is worth around US$80 million a year and growing at a 35% clip. Relative to the US, there are fewer competitors. 'We look forward to the commercialisation in Bahrain and further expanding our sales and marketing efforts in the region,' Renerve director Dr Julian Chick says. Emyria is ecstatic over PTSD trial results Better known as a party drug among the younger set, MDMA (Molly or ecstasy) appears to have hit the mark as a treatment for post-traumatic stress disorder (PTSD). In a six-month follow-up to its early-stage trial, Emyria (ASX:EMD) reports that five out of eight patients had improved to the extent that they no longer met the criteria for PTSD diagnosis. The company says the patients achieved an average 55.5% reduction in PTSD symptom severity, as measured by a five-point scale known as PCL-5. On a self-reported measure, they also achieved a 121% improvement in quality of life. Th company says these results suggest 'clinically meaningful and sustained improvements in a patient cohort previously considered treatment resistant'. The ongoing trial has enrolled 30 patients across two Perth sites. While psychiatrists oversee the patients, the results were achieved in a 'real world' setting. Difficult to treat, PTSD affects up to 11% of Australian adults, or 800,000 individuals.
